Servier investing in Latin America

19 July 2001

Servier of France says that, as part of its aim to double the number ofproducts it sells in Latin America, the firm is going to invest $40 million, split between a new factory in the Rio de Janeiro area and a research center elsewhere in Brazil. Once the new factory comes on-line, due in 2003, Servier will no longer have to import medicines into the region, according to the South American Business Information news service.

Looking to boost Brazilian sales

At the moment, the company sells 14 products in Latin America, bringing in revenues of $72 million annually, of which $23.2 million is earned in Brazil. A report in Gazeta Mercantil noted that Servier is hoping to increase its Brazilian income to $70 million by 2005.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight